Rosalyn Adam

Publications

1. Pediatric bladder tissue engineering: Where have we been and where do we go next? J Pediatr Urol. 2025 Jan 03. View Abstract
2. Investigation of the impact of bromodomain inhibition on cytoskeleton stability and contraction. Cell Commun Signal. 2024 03 16; 22(1):184. View Abstract
3. Machine Learning-Based Classification of Transcriptome Signatures of Non-Ulcerative Bladder Pain Syndrome. Int J Mol Sci. 2024 Jan 26; 25(3). View Abstract
4. Machine Learning-based Classification of transcriptome Signatures of non-ulcerative Bladder Pain Syndrome. bioRxiv. 2024 Jan 08. View Abstract
5. Machine Learning Made Easy (MLme): a comprehensive toolkit for machine learning-driven data analysis. Gigascience. 2024 01 02; 13. View Abstract
6. Integrated omics analysis unveils a DNA damage response to neurogenic injury. bioRxiv. 2023 Dec 10. View Abstract
7. Investigation of the impact of bromodomain inhibition on cytoskeleton stability and contraction. bioRxiv. 2023 Nov 14. View Abstract
8. Bioinformatics in urology - molecular characterization of pathophysiology and response to treatment. Nat Rev Urol. 2024 04; 21(4):214-242. View Abstract
9. Machine Learning Made Easy (MLme): A Comprehensive Toolkit for Machine Learning-Driven Data Analysis. bioRxiv. 2023 Jul 04. View Abstract
10. SpheroScan: A User-Friendly Deep Learning Tool for Spheroid Image Analysis. bioRxiv. 2023 Jun 28. View Abstract
11. SpheroScan: a user-friendly deep learning tool for spheroid image analysis. Gigascience. 2022 12 28; 12. View Abstract
12. MLcps: machine learning cumulative performance score for classification problems. Gigascience. 2022 12 28; 12. View Abstract
13. Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nat Commun. 2022 Dec 23; 13(1):7920. View Abstract
14. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation. Nat Commun. 2022 11 02; 13(1):6575. View Abstract
15. Neuropilin 2 Is a Novel Regulator of Distal Colon Contractility. Am J Pathol. 2022 11; 192(11):1592-1603. View Abstract
16. A Comprehensive Transcriptomic Analysis of Arsenic-Induced Bladder Carcinogenesis. Cells. 2022 08 05; 11(15). View Abstract
17. Wnt Site Signaling Inhibitor Secreted Frizzled-Related Protein 3 Protects Mitral Valve Endothelium From Myocardial Infarction-Induced Endothelial-to-Mesenchymal Transition. J Am Heart Assoc. 2022 04 05; 11(7):e023695. View Abstract
18. Integrated mRNA-miRNA transcriptome analysis of bladder biopsies from patients with bladder pain syndrome identifies signaling alterations contributing to the disease pathogenesis. BMC Urol. 2021 Dec 07; 21(1):172. View Abstract
19. Knockin mouse models demonstrate differential contributions of synaptotagmin-1 and -2 as receptors for botulinum neurotoxins. PLoS Pathog. 2021 10; 17(10):e1009994. View Abstract
20. Urinary Tract Infections in Children with Vesicoureteral Reflux Are Accompanied by Alterations in Urinary Microbiota and Metabolome Profiles. Eur Urol. 2022 02; 81(2):151-154. View Abstract
21. Interaction of TLK1 and AKTIP as a Potential Regulator of AKT Activation in Castration-Resistant Prostate Cancer Progression. Pathophysiology. 2021 Jul 20; 28(3):339-354. View Abstract
22. Erratum. Inhibition of TNF-a Improves the Bladder Dysfunction That Is Associated With Type 2 Diabetes. Diabetes 2012;61:2134-2145. Diabetes. 2021 Jun; 70(6):1416. View Abstract
23. Molecular mechanisms of esophageal epithelial regeneration following repair of surgical defects with acellular silk fibroin grafts. Sci Rep. 2021 03 29; 11(1):7086. View Abstract
24. A Single Cell Dissociation Approach for Molecular Analysis of Urinary Bladder in the Mouse Following Spinal Cord Injury. J Vis Exp. 2020 06 17; (160). View Abstract
25. Novel discoveries in urology: big data to microbiome - highlights of the society for basic urologic research 2019 annual meeting. Am J Clin Exp Urol. 2020; 8(2):73-75. View Abstract
26. Systems analysis of benign bladder disorders: insights from omics analysis. Am J Physiol Renal Physiol. 2020 04 01; 318(4):F901-F910. View Abstract
27. A multi-omics approach to understanding the field effect in bladder cancer. Transl Androl Urol. 2019 Dec; 8(6):775-778. View Abstract
28. Multicentre study of perioperative versus adjuvant chemotherapy for resectable colorectal liver metastases. BJS Open. 2019 10; 3(5):678-686. View Abstract
29. MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 06; 17(6):1294-1304. View Abstract
30. Concordant miRNA and mRNA expression profiles in humans and mice with bladder outlet obstruction. Am J Clin Exp Urol. 2018; 6(6):219-233. View Abstract
31. Genome-wide CRISPR screens for Shiga toxins and ricin reveal Golgi proteins critical for glycosylation. PLoS Biol. 2018 11; 16(11):e2006951. View Abstract
32. Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. Bladder Cancer. 2018 Oct 29; 4(4):429-440. View Abstract
33. Inosine - a Multifunctional Treatment for Complications of Neurologic Injury. Cell Physiol Biochem. 2018; 49(6):2293-2303. View Abstract
34. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Critical Mediator of Tissue Repair and Regeneration. Am J Pathol. 2018 11; 188(11):2446-2456. View Abstract
35. Canadian Surgery Forum 2018: St. John's, NL Sept. 13-15, 2018. Can J Surg. 2018 Aug; 61(4 Suppl 1):S94-S174. View Abstract
36. The role of the mucosa in modulation of evoked responses in the spinal cord injured rat bladder. Neurourol Urodyn. 2018 06; 37(5):1583-1593. View Abstract
37. Mode of Surgical Injury Influences the Source of Urothelial Progenitors during Bladder Defect Repair. Stem Cell Reports. 2017 12 12; 9(6):2005-2017. View Abstract
38. The Cytotoxicity and Genotoxicity of Particulate and Soluble Cobalt in Human Urothelial Cells. Biol Trace Elem Res. 2017 Nov; 180(1):48-55. View Abstract
39. Inosine attenuates spontaneous activity in the rat neurogenic bladder through an A2B pathway. Sci Rep. 2017 03 15; 7:44416. View Abstract
40. MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. Cancer Res. 2017 05 01; 77(9):2306-2317. View Abstract
41. Deletion of neuropilin 2 enhances detrusor contractility following bladder outlet obstruction. JCI Insight. 2017 02 09; 2(3):e90617. View Abstract
42. Inflammation and Lymphedema Are Exacerbated and Prolonged by Neuropilin 2 Deficiency. Am J Pathol. 2016 11; 186(11):2803-2812. View Abstract
43. Hexavalent chromium induces chromosome instability in human urothelial cells. Toxicol Appl Pharmacol. 2016 Apr 01; 296:54-60. View Abstract
44. Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury. PLoS One. 2015; 10(11):e0141492. View Abstract
45. Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: a paradigm for molecular subtyping of urothelial cell carcinoma of the bladder. Urol Oncol. 2015 Oct; 33(10):444-50. View Abstract
46. Mutations in TBX18 Cause Dominant Urinary Tract Malformations via Transcriptional Dysregulation of Ureter Development. Am J Hum Genet. 2015 Aug 06; 97(2):291-301. View Abstract
47. Regulation of microtubule dynamics by DIAPH3 influences amoeboid tumor cell mechanics and sensitivity to taxanes. Sci Rep. 2015 Jul 16; 5:12136. View Abstract
48. Platelet Derived Growth Factor Has a Role in Pressure Induced Bladder Smooth Muscle Cell Hyperplasia and Acts in a Paracrine Way. J Urol. 2015 Dec; 194(6):1797-805. View Abstract
49. Dynamic reciprocity in cell-scaffold interactions. Adv Drug Deliv Rev. 2015 Mar; 82-83:77-85. View Abstract
50. Pathophysiology and animal modeling of underactive bladder. Int Urol Nephrol. 2014 Sep; 46 Suppl 1:S11-21. View Abstract
51. Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):512-6. View Abstract
52. Integration of proteomic and transcriptomic profiles identifies a novel PDGF-MYC network in human smooth muscle cells. Cell Commun Signal. 2014 Aug 01; 12:44. View Abstract
53. The use of bi-layer silk fibroin scaffolds and small intestinal submucosa matrices to support bladder tissue regeneration in a rat model of spinal cord injury. Biomaterials. 2014 Aug; 35(26):7452-9. View Abstract
54. Acellular bi-layer silk fibroin scaffolds support tissue regeneration in a rabbit model of onlay urethroplasty. PLoS One. 2014; 9(3):e91592. View Abstract
55. Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Dev Cell. 2013 Sep 16; 26(5):469-482. View Abstract
56. Bladder tissue regeneration using acellular bi-layer silk scaffolds in a large animal model of augmentation cystoplasty. Biomaterials. 2013 Nov; 34(34):8681-9. View Abstract
57. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. Oncogene. 2014 Jun 19; 33(25):3235-45. View Abstract
58. Is unexpected peritoneal carcinomatosis still a contraindication for resection of colorectal liver metastases? Combined resection of colorectal liver metastases with peritoneal deposits discovered intra-operatively. Eur J Surg Oncol. 2013 Sep; 39(9):981-7. View Abstract
59. Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. J Pathol. 2013 Sep; 231(1):77-87. View Abstract
60. Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia. 2013 Jul; 15(7):749-60. View Abstract
61. The impact of discrete modes of spinal cord injury on bladder muscle contractility. BMC Urol. 2013 May 13; 13:24. View Abstract
62. The performance of silk scaffolds in a rat model of augmentation cystoplasty. Biomaterials. 2013 Jul; 34(20):4758-65. View Abstract
63. Evaluation of silk biomaterials in combination with extracellular matrix coatings for bladder tissue engineering with primary and pluripotent cells. PLoS One. 2013; 8(2):e56237. View Abstract
64. JunB mediates basal- and TGFß1-induced smooth muscle cell contractility. PLoS One. 2013; 8(1):e53430. View Abstract
65. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012 Nov; 181(5):1573-84. View Abstract
66. Inhibition of TNF-a improves the bladder dysfunction that is associated with type 2 diabetes. Diabetes. 2012 Aug; 61(8):2134-45. View Abstract
67. Increased smooth muscle contractility in mice deficient for neuropilin 2. Am J Pathol. 2012 Aug; 181(2):548-59. View Abstract
68. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med. 2012 Aug; 4(8):743-60. View Abstract
69. On the (C)USP(2a) of new targets for bladder cancer therapy? Cell Cycle. 2012 Apr 01; 11(7):1270-1. View Abstract
70. FosB regulates stretch-induced expression of extracellular matrix proteins in smooth muscle. Am J Pathol. 2011 Dec; 179(6):2977-89. View Abstract
71. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol. 2013 Aug; 31(6):802-11. View Abstract
72. The effect of manipulation of silk scaffold fabrication parameters on matrix performance in a murine model of bladder augmentation. Biomaterials. 2011 Oct; 32(30):7562-70. View Abstract
73. A Tbx1-Six1/Eya1-Fgf8 genetic pathway controls mammalian cardiovascular and craniofacial morphogenesis. J Clin Invest. 2011 Apr; 121(4):1585-95. View Abstract
74. An hTERT-immortalized human urothelial cell line that responds to anti-proliferative factor. In Vitro Cell Dev Biol Anim. 2011 Jan; 47(1):2-9. View Abstract
75. Evaluation of gel spun silk-based biomaterials in a murine model of bladder augmentation. Biomaterials. 2011 Jan; 32(3):808-18. View Abstract
76. Fluidization and resolidification of the human bladder smooth muscle cell in response to transient stretch. PLoS One. 2010 Aug 06; 5(8):e12035. View Abstract
77. All-trans retinoic acid directs urothelial specification of murine embryonic stem cells via GATA4/6 signaling mechanisms. PLoS One. 2010 Jul 13; 5(7):e11513. View Abstract
78. Histone deacetylase inhibitors and bladder cancer. J Urol. 2010 Jun; 183(6):2120-1. View Abstract
79. An Akt- and Fra-1-dependent pathway mediates platelet-derived growth factor-induced expression of thrombomodulin, a novel regulator of smooth muscle cell migration. Am J Pathol. 2010 Jul; 177(1):119-31. View Abstract
80. Cell signaling in kidney cancer. J Urol. 2009 Dec; 182(6):2555-6. View Abstract
81. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009 Jul 01; 69(13):5601-9. View Abstract
82. Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res. 2009 Mar 15; 69(6):2210-8. View Abstract
83. Rapid preparation of nuclei-depleted detergent-resistant membrane fractions suitable for proteomics analysis. BMC Cell Biol. 2008 Jun 05; 9:30. View Abstract
84. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle. 2008 Jul 15; 7(14):2257-67. View Abstract
85. The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1. EMBO J. 2007 Oct 31; 26(21):4523-34. View Abstract
86. GATA-6 mediates human bladder smooth muscle differentiation: involvement of a novel enhancer element in regulating alpha-smooth muscle actin gene expression. Am J Physiol Cell Physiol. 2007 Sep; 293(3):C1093-102. View Abstract
87. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 2007 Jul 01; 67(13):6238-46. View Abstract
88. The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer. Mol Endocrinol. 2007 Sep; 21(9):2056-70. View Abstract
89. Cyclooxygenase-2 in transitional cell carcinoma--a legitimate target? J Urol. 2007 Mar; 177(3):818-9. View Abstract
90. Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes. Steroids. 2007 Feb; 72(2):210-7. View Abstract
91. Inhibition of EGFR signaling abrogates smooth muscle proliferation resulting from sustained distension of the urinary bladder. Lab Invest. 2006 Dec; 86(12):1293-302. View Abstract
92. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo). 2006 Oct; 61(5):401-8. View Abstract
93. Effective salvage therapy of liver-only colorectal cancer metastases with chronomodulated irinotecan-fluorouracil-oxaliplatin via hepatic artery infusion. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3585. View Abstract
94. Behavioral profiling of human transitional cell carcinoma ex vivo. Cancer Res. 2006 Mar 15; 66(6):3078-86. View Abstract
95. A quantitative proteomic analysis of growth factor-induced compositional changes in lipid rafts of human smooth muscle cells. Proteomics. 2005 Dec; 5(18):4733-42. View Abstract
96. JNK/SAPK and p38 SAPK-2 mediate mechanical stretch-induced apoptosis via caspase-3 and -9 in NRK-52E renal epithelial cells. Nephron Exp Nephrol. 2006; 102(2):e49-61. View Abstract
97. Recent insights into the cell biology of bladder smooth muscle. Nephron Exp Nephrol. 2006; 102(1):e1-7. View Abstract
98. Trafficking of nuclear heparin-binding epidermal growth factor-like growth factor into an epidermal growth factor receptor-dependent autocrine loop in response to oxidative stress. Cancer Res. 2005 Sep 15; 65(18):8242-9. View Abstract
99. Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. Neuropathology. 2005 Sep; 25(3):178-87. View Abstract
100. Three-drug chronotherapy via hepatic artery as salvage treatment for patients with liver-only metastases from colorectal cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):3616. View Abstract
101. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005 Apr; 115(4):959-68. View Abstract
102. Induction of smooth muscle cell-like phenotype in marrow-derived cells among regenerating urinary bladder smooth muscle cells. Am J Pathol. 2005 Feb; 166(2):565-73. View Abstract
103. Growth and stretch response of human exstrophy bladder smooth muscle cells: molecular evidence of normal intrinsic function. BJU Int. 2005 Jan; 95(1):144-8. View Abstract
104. An oxidative stress mechanism mediates chelerythrine-induced heparin-binding EGF-like growth factor ectodomain shedding. J Cell Biochem. 2005 Jan 01; 94(1):39-49. View Abstract
105. Caveolae are negative regulators of transforming growth factor-beta1 signaling in ureteral smooth muscle cells. J Urol. 2004 Dec; 172(6 Pt 1):2451-5. View Abstract
106. Mechanical stretch is a highly selective regulator of gene expression in human bladder smooth muscle cells. Physiol Genomics. 2004 Dec 15; 20(1):36-44. View Abstract
107. Mechanical strain delivers anti-apoptotic and proliferative signals to gingival fibroblasts. J Dent Res. 2004 Aug; 83(8):596-601. View Abstract
108. Rho-kinase inhibitors: potential therapeutics for benign prostate hyperplasia. J Urol. 2003 Dec; 170(6 Pt 1):2523-4. View Abstract
109. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology. 2004 Feb; 145(2):613-9. View Abstract
110. Signaling through PI3K/Akt mediates stretch and PDGF-BB-dependent DNA synthesis in bladder smooth muscle cells. J Urol. 2003 Jun; 169(6):2388-93. View Abstract
111. Platelet derived growth factor-BB is a potent mitogen for rat ureteral and human bladder smooth muscle cells: dependence on lipid rafts for cell signaling. J Urol. 2003 Mar; 169(3):1165-70. View Abstract
112. Calcium regulates the PI3K-Akt pathway in stretched osteoblasts. FEBS Lett. 2003 Feb 11; 536(1-3):193-7. View Abstract
113. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res. 2003 Jan 15; 63(2):484-90. View Abstract
114. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology. 2002 Dec; 143(12):4599-608. View Abstract
115. Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab Invest. 2002 Dec; 82(12):1755-64. View Abstract
116. The decision to undergo DNA or protein synthesis is determined by the degree of mechanical deformation in human bladder muscle cells. Urology. 2002 May; 59(5):779-83. View Abstract
117. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res. 2002 Mar 01; 62(5):1549-54. View Abstract
118. A novel method for implantation of LNCaP prostate tumor cells under the renal capsule. In Vitro Cell Dev Biol Anim. 2001 Jun; 37(6):360-2. View Abstract
119. CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun. 2001 Apr 06; 282(3):729-34. View Abstract
120. Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro. J Urol. 2001 Jan; 165(1):284-8. View Abstract
121. Cyclic stretch activates p38 SAPK2-, ErbB2-, and AT1-dependent signaling in bladder smooth muscle cells. Am J Physiol Cell Physiol. 2000 Oct; 279(4):C1155-67. View Abstract
122. Heparin-binding EGF-like growth factor is up-regulated in the obstructed kidney in a cell- and region-specific manner and acts to inhibit apoptosis. Am J Pathol. 2000 Mar; 156(3):889-98. View Abstract
123. Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate. Endocrinology. 1999 Dec; 140(12):5866-75. View Abstract
124. Amphiregulin Is Coordinately Expressed with Heparin-Binding Epidermal Growth Factor-Like Growth Factor in the Interstitial Smooth Muscle of the Human Prostate1. Endocrinology. 1999 Dec 01; 140(12):5866-5875. View Abstract
125. Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction. Lab Invest. 1999 Nov; 79(11):1335-45. View Abstract
126. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999 Sep; 54(3):523-7. View Abstract
127. AP-1 mediates stretch-induced expression of HB-EGF in bladder smooth muscle cells. Am J Physiol. 1999 08; 277(2):C294-301. View Abstract
128. Cell-specific activation of the HB-EGF and ErbB1 genes by stretch in primary human bladder cells. In Vitro Cell Dev Biol Anim. 1999 Jul-Aug; 35(7):371-5. View Abstract
129. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 1999 Jun 15; 59(12):2891-7. View Abstract
130. Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J Cell Biochem. 1998 May 01; 69(2):143-53. View Abstract
131. Heparin-binding EGF-like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J Cell Biochem. 1998 Mar 01; 68(3):328-38. View Abstract
132. Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J Clin Invest. 1997 Mar 01; 99(5):1028-36. View Abstract
133. Induction of anchorage-independent growth by amphiregulin. Growth Factors. 1996; 13(3-4):193-203. View Abstract
134. Modulation of the receptor binding affinity of amphiregulin by modification of its carboxyl terminal tail. Biochim Biophys Acta. 1995 Apr 06; 1266(1):83-90. View Abstract
135. [Long-term follow-up of patients with borderline tumors of the ovaries]. Gynakol Rundsch. 1990; 30 Suppl 1:48-50. View Abstract
Show All Publications Show Fewer Publications